Protecting Intellectual Property in Engagements with CMOs

June 15, 2015
Jennifer L. Collins

Jennifer L. Collins is a technology and licensing attorney with Morningstar Law Group.

BioPharm International, BioPharm International-06-15-2015, Volume 2015 eBook, Issue 1

Important IP contractual provisions should be included when working with CMOs.


Biotechnology and pharmaceutical companies often engage contract CMOs to assist with the development of their drugs. This type of arrangement naturally involves the development of intellectual property (IP), so it is important for both the CMO and the sponsor to identify pre-existing intellectual property and also define how rights to new IP will be allocated, protected, and enforced by and between the companies.